| Drug ID: | Drug52 |
|---|---|
| Drug Name: | Iron |
| CID: | 23925 |
| DrugBank ID: | DB01592 |
| Modality: | Small Molecule |
| Groups: | approved |
| US Approved: | NO |
| Other Approved: | YES |
| Identifier: | NCT01017614, , NCT03441893 |
| Molecular Formula: | Fe |
| Molecular Weight: | 55.84 g/mol |
| Isomeric SMILES: | [Fe] |
| Synonyms: | IRON; 7439-89-6; Iron, elemental; Ferrum; Iron powder; Remko; Armco iron; Ferrovac E; Ancor B; hierro |
| Phase 0: | 4 |
| Phase 1: | 19 |
| Phase 2: | 46 |
| Phase 3: | 81 |
| Phase 4: | 92 |
| Description: | A metallic element found in certain minerals, in nearly all soils, and in mineral waters. It is an essential constituent of hemoglobin, cytochrome, and other components of respiratory enzyme systems. Its chief functions are in the transport of oxygen to tissue (hemoglobin) and in cellular oxidation mechanisms. Depletion of iron stores may result in iron-deficiency anemia. Iron is used to build up the blood in anemia. |
Molecular Structure
Knowledge Graph
| dtID | CID | Compound Name | Gene ID | Gene Name | Species | PubMed IDs | Action |
|---|---|---|---|---|---|---|---|
| dt472 | 23925 | Iron | 3040 | HBA2 | Homo sapiens (human) | Activator | |
| dt473 | 23925 | Iron | 7037 | TFRC | Homo sapiens (human) | 16564538 | None |
| dt474 | 23925 | Iron | 54583 | EGLN1 | Homo sapiens (human) | 16649251 | None |
| dt475 | 23925 | Iron | 55869 | HDAC8 | Homo sapiens (human) | 16681389 | Cofactor |
| dt476 | 23925 | Iron | 51327 | AHSP | Homo sapiens (human) | 16901899 | None |
| dt477 | 23925 | Iron | 2395 | FXN | Homo sapiens (human) | 16911956 | None |
| dt478 | 23925 | Iron | 2495 | FTH1 | Homo sapiens (human) | 17070541 | None |
| dt479 | 23925 | Iron | 2237 | FEN1 | Homo sapiens (human) | 20622253 | None |
| dt480 | 23925 | Iron | 79661 | NEIL1 | Homo sapiens (human) | 20622253 | None |
| dt481 | 23925 | Iron | 252969 | NEIL2 | Homo sapiens (human) | 20622253 | None |
- No data available
Phase Distribution
Phase Description
- Phase 0: Exploratory trials to assess drug behavior in humans
- Phase 1: Safety trials to determine safe dosage range
- Phase 2: Efficacy trials to evaluate therapeutic effects
- Phase 3: Large-scale trials to confirm efficacy and safety
- Phase 4: Post-marketing surveillance for long-term safety and efficacy
| Trial ID | Title | Phase | Status | Sponsor | Indications | Interventions | |
|---|---|---|---|---|---|---|---|
| NCT06321887 | EffiCacy and sAfEty of Low doSe orAl iRon for Anaemia in IBD | PHASE3 | RECRUITING | Liverpool University Hospitals NHS Foundation Trust | Inflammatory Bowel Disease|Iron Deficiency Anemia | DRUG: Ferrous fumarate syrup 2.5ml/70mg (22.5mg e… | Details |
| NCT01438372 | IV Iron Sucrose vs Oral FeSO4 in Treating IDA in Pediatric IBD | PHASE2 | WITHDRAWN | Wayne State University | Iron Deficiency Anemia|Inflammatory Bowel Disease | DRUG: Intravenous iron sucrose|DRUG: Oral ferrous… | Details |
| NCT02774057 | Trial of Captafer vs. Oral Iron Sulfate in the Treatment of Iron Deficiency Anemia in Patients With IBD | PHASE4 | UNKNOWN | American University of Beirut Medical Center | Iron Deficiency Anemia|Inflammatory Bowel Disease | DRUG: Captafer|DRUG: Iron Sulfate | Details |
| NCT02760940 | Anemia in Inflammatory Bowel Disease | PHASE4 | UNKNOWN | Federal University of Juiz de Fora | Anemia|Bowel Diseases, Inflammatory | DRUG: oral liposomal iron | Details |
| NCT03376230 | Role of the Chemical Environment in the Pathogenesis of Inflammatory Bowel Disease | None | TERMINATED | University Hospital, Lille | Inflammatory Bowel Diseases | OTHER: Collect of blood, urines, and intestinal b… | Details |
| NCT03457571 | Clinical Observational Study: IBD Patients With Restless-legs-syndrome and Iron Deficiency Syndrome | None | COMPLETED | Charite University, Berlin, Germany | Inflammatory Bowel Diseases|Restless Legs Syndrom… | None | Details |
| NCT00810030 | FERINJECT for Correction of Anaemia in IBD Patients, FER-IBD-COR | PHASE3 | COMPLETED | Vifor Pharma | Inflammatory Bowel Disease|Anemia|Iron Deficiency… | DRUG: Ferric carboxymaltose|DRUG: Iron Sucrose | Details |
| NCT06120322 | Machine Learning Approach to Study the Interactions Between Environment and Intestinal Tissue Homeostasis in IBD | None | NOT_YET_RECRUITING | IRCCS San Raffaele | Diabetes Mellitus, Type 1|Ulcerative Colitis | OTHER: Environmental factor monitoring; collectio… | Details |
| NCT05225545 | Sucrosomial Iron vs. Oral Iron Sulfate for the Treatment of Iron Deficiency Anemia in Patients With Ulcerative Colitis | PHASE3 | RECRUITING | American University of Beirut Medical Center | Anemia, Iron Deficiency|Ulcerative Colitis | DRUG: Sucrosomial Iron|DRUG: Oral Iron | Details |
| NCT03282903 | The PRognostic Effect of Environmental Factors in Crohn's and Colitis | None | COMPLETED | University of Edinburgh | Inflammatory Bowel Diseases|Crohn Disease|Ulcerat… | None | Details |
| NCT03247816 | Feraccru Real World Effectiveness Study in Hospital Practice ( FRESH ) | None | COMPLETED | Shield Therapeutics | Anemia, Iron Deficiency|Inflammatory Bowel Diseas… | None | Details |
| NCT01017614 | Iron Oligosaccharide in Inflammatory Bowel Disease Subjects With Iron Deficiency Anaemia | PHASE3 | COMPLETED | Pharmacosmos A/S | Inflammatory Bowel Disease | DRUG: Monofer; DRUG: Iron Sulphate | Details |
| NCT05176795 | Host-microbiota-environment Interactions | Not Available | RECRUITING | University Hospital, Clermont-Ferrand | Juvenile Idiopathic Arthritis; Diabetes type1; In… | OTHER: Stool sample | Details |
| ChiCTR2500100314 | Analysis of iron-related indexes and disease association in patients with inflammatory bowel disease | Not Available | Not Recruiting | Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University | Inflammatory bowel disease | IBD patients:None; | Details |
| DRKS00034606 | CEDATA GPGE Patient Registry - Registry for chronic inflammatory bowel diseases in children and adolescents - CEDATA | Not Available | Recruiting | Gesellschaft f Piatrische Gastroenterologie und Ernrung e. V. | Inflammatory Bowel Disease K50-K52;Noninfective … | Group 1: Health Care Data is entered into an onli… | Details |
| NCT02517151 | Iron Supplementation in Inflammatory Bowel Disease (IBD) Patients With Chronic Fatigue | PHASE2 | UNKNOWN | Istituto Clinico Humanitas | Chronic Fatigue|Inflammatory Bowel Disease | DRUG: Ferric carboxymaltose|DRUG: Placebo | Details |
| ACTRN12624000016538 | Longitudinal study of diet, lifestyle and biomarker predictors of pouchitis | Not Available | Not Recruiting | Monash University | Inflammatory bowel disease;familial adenomatous p… | We will be following individuals with an ileoanal… | Details |
| ChiCTR2200066959 | Study on the effect of iron supplementation on the efficacy of anti-TNF-a monoclonal antibody in patients with IBD | Not Available | Not Recruiting | Sir Run Run Shaw Hospital, Zhejiang University School of Medicine | Inflammatory bowel disease | Intervention group :iron isomaltoside;Control gro… | Details |
| ChiCTR2200066056 | A comparative study of iron isomaltoside versus traditional iron supplements in patients with inflammatory bowel diseases and iron deficiency anemia | Not Available | Not Recruiting | Sir Run Run Shaw Hospital, Zhejiang University School of Medicine | Inflammatory bowel disease | Intervention group:iron isomaltoside;Control grou… | Details |
| EUCTR2022-000894-16-NL | Predicting Response to Iron Supplementation in Patients with active Inflammatory Bowel Disease_ - PRIme | PHASE4 | Not Recruiting | Leiden University Medical Center | Inflammatory Bowel Disease MedDRA version: 20.0_… | Trade Name: Feraccru Pharmaceutical Form: Capsule… | Details |
| Disease ID | Disease Name | Definition | Category | Related Drugs | Mechanism | |
|---|---|---|---|---|---|---|
| 1.0 | Crohn's disease | An intestinal disease that involves inflammation located_in intestine. | disease of anatomical entity gastrointestinal system disease, intestinal disease, inflammatory bowel disease | Obiltoxaximab; Budesonide; Hydrocortisone acetate; Sulfasalazine; Ursodeoxycholic acid; Pegunigalsidase alfa; Imiglucerase; Bictegravir; Taliglucerase alfa; Etelcalcetide; Cimetidine; Desonide | Crohn's disease is a relapsing systemic inflammatory diseas… | Details |
| 2.0 | ulcerative colitis | A colitis that is predominantly confined to the mucosa located_in colon and includes characteristic ulcers, or open sores. | disease of anatomical entity, gastrointestinal system disease, autoimmune disease of gastrointestinal tract; intestinal disease, inflammatory bowel disease, colitis; disease, primary immunodeficiency disease, autoimmune disease, autoimmune disease of gastrointestinal tract | Mirikizumab; Olsalazine; Balsalazide; Sulfasalazine; Budesonide; Hydrocortisone acetate; Tixocortol; Kappadione; Teicoplanin; Atezolizumab; Gamolenic acid; Upadacitinib | No abstract available | Details |
| Strategy ID | Therapeutic Strategy | Synonyms | Related Drugs | Mechanism | |
|---|---|---|---|---|---|
| S01 | Anti-inflammatory | inflammatory | 5-Aminosalicylates (5-ASAs); corticosteroids | Crohn's disease and ulcerative colitis are the two main com… | Details |
| S02 | Immunosuppression | Classic immunosuppressive drugs | azathioprine; 6-mercaptopurine; methotrexate; ciclosporin-A; tacrolimus | Ciclosporin-A and tacrolimus bind to specific intracellular… | Details |
| S03 | Anti-TNF agents | Tumor necrosis factor | infliximab; adalimumab; golimumab; certolizumab pegol | TNF is produced by various immune and non-immune cells in t… | Details |
| S04 | T-cell homing and retention | T-cell trafficking | vedolizumab; anti-MAdCAM1 antibodies ; etrolizumab | Inhibition of the interaction between α4β7 integrins on T c… | Details |
| S07 | Blockade of cytokine | Cytokine signalling | apremilast; roflumilast; filgotinib; tofacitinib; ABT494; ABT-874; ustekinumab; isankizumab; LY-2525623; AMG139; MEDI2079; guselkumab | Various T-cell subsets, their differentiation pathways and … | Details |
| S08 | Strengthening barrier function | Modulation of barrier function | phosphatidylcholine (lecithin); imiquimod; mongersen | Escherichia coli Nissle (EcN) is a nonpathogenic Gram-negat… | Details |
| S11 | Improveming Intestinal Microecology | the intestinal microbiota | antibiotics; probiotics; prebiotics; postbiotics; synbiotics; fecal microbiota transplantation (FMT) | The imbalance between beneficial bacteria and harmful patho… | Details |
Inpatient management of iron deficiency anemia in pediatric patients with infla…
PMID: 38596440
Year: 2024
Relationship Type:
Treatment
Score: 9.5
BACKGROUND: Screening for iron deficiency anemia (IDA) is important in managing pediatric patients with inflammatory bowel disease (IBD). Concerns re…
Environmental Exposure to Trace Elements and Heavy Metals Preceding the Clinica…
PMID: 38544908
Year: 2024
Relationship Type:
Clinical Trial
Score: 9.5
BACKGROUND: The immune dysregulation underlying inflammatory bowel disease (IBD) can start years before the diagnosis, but the role of triggering fac…
Ultrarapid Iron Polymaltose Infusions Are Safe for Management of Iron Deficiency
PMID: 38476307
Year: 2023
Relationship Type:
Treatment
Score: 9.5
INTRODUCTION: Iron deficiency is a common condition, especially among patients with kidney and heart failure and inflammatory bowel disease. Intraven…
Cost-utility analysis of ferric derisomaltose versus ferric carboxymaltose in p…
PMID: 38391240
Year: 2024
Relationship Type:
Treatment
Score: 9.5
AIMS: Anemia is the most common extraintestinal complication of inflammatory bowel disease (IBD), with approximately half of cases caused by iron def…
Metabolic Nanoregulator Remodels Gut Microenvironment for Treatment of Inflamma…
PMID: 38390866
Year: 2024
Relationship Type:
Treatment
Score: 9.5
Inflammatory bowel disease (IBD) is strongly related to the occurrence of accumulation of toxic reactive oxygen species (ROS), inflammation of the mu…
Mouse Adaptation of Human Inflammatory Bowel Diseases Microbiota Enhances Colon…
PMID: 38328082
Year: 2024
Relationship Type:
Association
Score: 9.5
Understanding the cause vs consequence relationship of gut inflammation and microbial dysbiosis in inflammatory bowel diseases (IBD) requires a repro…
Early Life and Childhood Environmental Exposures, More Than Genetic Predisposit…
PMID: 38309494
Year: 2024
Relationship Type:
Association
Score: 9.5
BACKGROUND AND AIMS: Inflammatory bowel disease (IBD) develops from a combination of genetic and environmental factors. The aim of this study was to …
Predicting response to iron supplementation in patients with active inflammator…
PMID: 38296290
Year: 2024
Relationship Type:
Treatment
Score: 9.5
INTRODUCTION: Iron deficiency anaemia (IDA) is the most common systemic manifestation of inflammatory bowel disease (IBD) that has detrimental effect…
Butyrate Prevents the Pathogenic Anemia-Inflammation Circuit by Facilitating Ma…
PMID: 38235606
Year: 2024
Relationship Type:
Treatment
Score: 9.5
Most patients with inflammatory bowel disease (IBD) develop anemia, which is attributed to the dysregulation of iron metabolism. Reciprocally, impair…
The emerging role of hypoxia and environmental factors in inflammatory bowel di…
PMID: 38200624
Year: 2024
Relationship Type:
Association
Score: 9.5
Inflammatory bowel disease (IBD) is a chronic and debilitating disorder characterized by inflammation of the gastrointestinal tract. Despite extensiv…
Genomic inbreeding measures applied to a population of mice divergently selecte…
PMID: 38155710
Year: 2023
Relationship Type:
Association
Score: 9.5
This study aimed to compare different inbreeding measures estimated from pedigree and molecular data from two divergent mouse lines selected for envi…
Mitochondrial Stress Links Environmental Triggers with Pro-Inflammatory Signali…
PMID: 38136224
Year: 2023
Relationship Type:
Treatment
Score: 9.5
Inflammatory Bowel Diseases (IBD) are a group of chronic, inflammatory disorders of the gut. The incidence and activity of IBD are determined by both…
Houttuynia cordata thunb. alleviates inflammatory bowel disease by modulating i…
PMID: 38077358
Year: 2023
Relationship Type:
Treatment
Score: 9.5
Inflammatory bowel disease (IBD) is a complex group of chronic intestinal diseases, the cause of which has not yet been clarified, but it is widely b…
Intravenous iron therapy in pediatrics: who should get it and when is the right…
PMID: 38066925
Year: 2023
Relationship Type:
Treatment
Score: 9.5
Iron-deficiency anemia occurs most commonly in young children due to a low-iron diet and adolescent girls due to menstrual blood loss. However, child…
Iron chelation and supplementation: A comparison in the management of inflammat…
PMID: 38061132
Year: 2024
Relationship Type:
Adverse Effect
Score: 9.5
AIMS: Inflammatory Bowel Disease (IBD) is associated with systemic iron deficiency and has been managed with iron supplements which cause adverse sid…
Comprehensive analysis reveals key genes and environmental toxin exposures unde…
PMID: 38059894
Year: 2023
Relationship Type:
Treatment
Score: 9.5
BACKGROUND: UC is increasingly prevalent worldwide and represents a significant global disease burden. Although medical therapeutics are employed, th…
One advantageous reflection of iron metabolism in context of normal physiology …
PMID: 38057018
Year: 2023
Relationship Type:
Treatment
Score: 9.5
PURPOSE (BACKGROUND): The presented review is an updating of Iron metabolism in context of normal physiology and pathological phases. Iron is one of …
Ferroptosis-Mediated Immune Microenvironment and Therapeutic Response in Inflam…
PMID: 37943983
Year: 2023
Relationship Type:
Treatment
Score: 9.5
Inflammatory bowel disease (IBD) is a chronic inflammatory disorder characterized by dysregulated immune responses in the gastrointestinal tract. One…
The effect of iron therapy on oxidative stress and intestinal microbiota in inf…
PMID: 37918126
Year: 2023
Relationship Type:
Treatment
Score: 9.5
One in five patients with Inflammatory Bowel Disease (IBD) suffers from anemia, most frequently caused by iron deficiency. Anemia and iron deficiency…
Iron Deficiency Is Common after Restorative Proctocolectomy with Ileal Pouch-An…
PMID: 37901339
Year: 2023
Relationship Type:
Association
Score: 9.5
BACKGROUND: Micronutrient deficiencies may occur after restorative proctocolectomy (RPC) with ileal pouch-anal anastomosis (IPAA) in patients with ul…